查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462575

抗逆转录病毒药物市场 - 副产品（蛋白酶抑制剂、整合酶抑制剂、多类组合产品、NRTI、NNRTI）、类型（品牌、仿製药）、年龄组、配销通路- 全球预测，2024 年 - 2032 年

Anti-retroviral Drugs Market - By Product (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, NRTIs, NNRTIs), Type (Branded, Generic), Age Group, Distribution Channel - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于针对这些药物的研究激增，2024 年至 2032 年间，全球抗爱滋病毒药物市场规模的CAGR将超过 4.2%。随着爱滋病毒/爱滋病治疗方法的不断探索和新病毒株的出现，製药公司正在大力投资研发，以增强现有药物并发现新的治疗选择。

例如，2023 年12 月，根据《神经病学年鑑》上发表的一项研究，过去十年的大量病例报告表明了一种相关性：患有多发性硬化症(MS) 的个体开始针对HIV 进行抗逆转录病毒治疗，主要是为了控制病毒，观察到 MS 症状完全消失或疾病进展明显减慢。该研究表明，抗逆转录病毒药物可能会影响多发性硬化症的可能性，从而揭示了爱滋病毒治疗和多发性硬化症管理之间可能的关係。

这些努力导致发现了更有效的药物配方、改进的给药方法并减少了副作用，从而推动了对抗逆转录病毒药物的需求。此外，对病毒抗药性机制和个人化医疗方法的不断了解进一步推动了市场的成长。随着研究不断发现新的见解，对抗逆转录病毒药物的需求预计将持续存在，这为爱滋病毒/爱滋病及相关疾病的管理带来更好的结果。

整个抗逆转录病毒药物产业根据产品、类型、年龄层、配销通路和地区进行分类。

到 2032 年，核苷逆转录酶抑制剂 (NRTI) 领域将出现显着增长。因此，NRTI 在控制爱滋病毒/爱滋病、推动市场需求方面发挥着至关重要的作用。随着 NRTI 配方和组合的不断进步，与其经过验证的功效和安全性相一致，抗逆转录病毒药物市场的需求持续增长，确保了这一重要医学领域的持续研究和开发。

从 2023 年到 2032 年，仿製药领域的抗逆转录病毒药物市场份额将保持主导地位。仿製药抗逆转录病毒药物为品牌药物提供了具有成本效益的替代品，使爱滋病毒治疗在全球范围内更容易获得。它们的负担能力有利于广泛分配，特别是在获得医疗资源有限的低收入和中等收入国家。此外，仿製药抗逆转录病毒药物经过严格的监管审查，以确保品质和功效，增强医疗保健提供者和患者的信心。由于对负担得起的爱滋病毒治疗的需求持续存在，对仿製药抗逆转录病毒药物的需求仍然强劲，推动了市场成长并改善了全世界获得救命药物的机会。

2024年至2032年，欧洲抗爱滋病毒药物市场将呈现出值得称讚的复合CAGR。进行有效的疾病管理。此外，严格的法规确保了抗爱滋病毒药物的品质和安全，增强了消费者的信任。由于欧洲国家优先考虑爱滋病毒预防和治疗等公共卫生倡议，对这些药物的需求保持稳定。此外，持续的研发工作推动创新，进一步刺激整个欧洲对先进抗病毒疗法的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 加大研发投入
      • 爱滋病毒负担日益加重
      • 增加治疗爱滋病毒的新药的供应
    • 产业陷阱与挑战
      • 与药物相关的副作用
      • 治疗费用高
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

  • 主要趋势
  • 蛋白酶抑制剂
  • 整合酶抑制剂
  • 多类组合产品
  • 核苷逆转录酶抑制剂（NRTI）
  • 非核苷类逆转录酶抑制剂（NNRTI）
  • 其他药物类别

第 6 章：市场估计与预测：按类型，2018 - 2032

  • 主要趋势
  • 品牌化
  • 通用的

第 7 章：市场估计与预测：按年龄划分，2018 - 2032

  • 主要趋势
  • 成人
  • 儿科
  • 老年科

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药房
  • 网路药房

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 10 章：公司简介

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson and Johnson
  • Merck & Co, Inc.
  • Pfizer Inc.
  • Viatris Inc.
简介目录
Product Code: 8298

Global Anti-retroviral Drugs Market size will witness over 4.2% CAGR between 2024 and 2032 due to the surge in research and studies dedicated to these medications. With the ongoing exploration of HIV/AIDS treatments and the emergence of new strains, pharmaceutical companies are investing heavily in research and development to enhance existing drugs and discover novel therapeutic options.

For instance, in December 2023, as per a study published in the Annals of Neurology, numerous case reports over the past decade indicated a correlation: individuals with multiple sclerosis (MS) who initiated anti-retroviral therapy for HIV, primarily to manage the virus, observed either complete disappearance of MS symptoms or a marked deceleration in disease progression. The research suggested that anti-retrovirals may potentially impact the likelihood of developing MS, shedding light on a possible relationship between HIV treatment and MS management.

These efforts have led to the identification of more effective drug formulations, improved delivery methods, and reduced side effects, thereby driving demand for anti-retroviral drugs. Moreover, the expanding understanding of viral resistance mechanisms and personalized medicine approaches further fuels market growth. As research continues to uncover new insights, the demand for anti-retroviral drugs is expected to persist, offering hope for better outcomes in the management of HIV/AIDS and related conditions.

The overall anti-retroviral drugs Industry is classified based on the product, type, age group, distribution channel, and region.

The nucleoside reverse transcriptase inhibitors (NRTIs) segment will register significant growth by 2032. These drugs, a cornerstone of HIV treatment, inhibit the virus's ability to replicate by targeting its reverse transcriptase enzyme. As a result, NRTIs play a crucial role in managing HIV/AIDS, driving demand within the market. With ongoing advancements in NRTI formulations and combinations, in line with their proven efficacy and safety profiles, the demand for the Anti-retroviral Drugs Market continues to rise, ensuring continued research and development in this vital area of medicine.

Anti-retroviral drugs market share from the generic segment will withhold a dominant share from 2023-2032. Generic anti-retroviral drugs offer cost-effective alternatives to branded medications, making HIV treatment more accessible globally. Their affordability facilitates widespread distribution, particularly in low- and middle-income countries where access to healthcare resources is limited. Moreover, generic anti-retrovirals undergo rigorous regulatory scrutiny to ensure quality and efficacy, bolstering confidence among healthcare providers and patients. As the need for affordable HIV treatment persists, the demand for generic anti-retroviral drugs remains strong, driving market growth and improving access to life-saving medications worldwide.

Europe anti-retroviral drugs market will showcase a commendable CAGR from 2024 to 2032. With a strong healthcare infrastructure and a high prevalence of HIV/AIDS in certain regions, the continent relies on these medications for effective disease management. Additionally, stringent regulations ensure the quality and safety of anti-retroviral drugs, bolstering consumer trust. As European countries prioritize public health initiatives, including HIV prevention and treatment, the demand for these drugs remains steady. Moreover, ongoing research and development efforts drive innovation, further fueling the demand for advanced anti-retroviral therapies across Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing investment in research and development
      • 3.2.1.2 Growing burden of HIV
      • 3.2.1.3 Increase in availability of novel drugs for treatment of HIV
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects associated with the drugs
      • 3.2.2.2 High cost of the treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Protease inhibitors
  • 5.3 Integrase inhibitors
  • 5.4 Multi-class combination products
  • 5.5 Nucleoside reverse transcriptase inhibitors (NRTIs)
  • 5.6 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Branded
  • 6.3 Generic

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Adult
  • 7.3 Pediatric
  • 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Hospital pharmacy
  • 8.3 Retail pharmacy
  • 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 Boehringer Ingelheim International GmbH
  • 10.3 Bristol-Myers Squibb Company
  • 10.4 Cipla
  • 10.5 F. Hoffmann-La Roche Ltd
  • 10.6 Gilead Sciences, Inc.
  • 10.7 GlaxoSmithKline plc.
  • 10.8 Johnson and Johnson
  • 10.9 Merck & Co, Inc.
  • 10.10 Pfizer Inc.
  • 10.11 Viatris Inc.